IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical ...
The American Journal of Managed Care

Cryoablation Exhibits Advantages as Minimally Invasive Option for Early Breast Cancer

While offering advantages like faster recovery and high patient satisfaction, cryoablation for the treatment of early-stage breast cancer is still under investigation for effectiveness and requires ...
Nasdaq

New Standard of Care? IceCure Submits Final ICE3 Data To FDA, Minimally Invasive Cryoablation Shows Similar 5-year Recurrence Outcomes To Surgery With Hormone Therapy

IceCure’s ICE3 study was the largest controlled multicenter clinical trial ever performed for liquid nitrogen (LN2) based cryoablation of low-risk, early-stage malignant breast tumors. The five-year ...
Benzinga.com

Freezing Cancer With IceCure: ProSense Cryoablation System Receives FDA Marketing Authorization For Early-Stage Breast Cancer Treatment

IceCure Medical Ltd. (NASDAQ:ICCM), the developer of minimally invasive cryoablation technology that destroys tumors by freezing them, was granted marketing authorization from the U.S. Food and Drug ...
Everyday Health

This Freezing Technique Could Be the Next Frontier in Breast Cancer Treatment

A minimally invasive cryoablation procedure can destroy large tumors in patients unable to have surgery, a new study has found. A freezing technique called cryoablation was shown to be 90 percent ...
Bizcommunity

Steve Biko Academic Hospital performs pioneering cryoablation procedure

The Gauteng MEC for Health & Wellness, Nomantu Nkomo-Ralehoko, announced on X (Twitter) that the Steve Biko Academic Hospital ...
Morningstar

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

"ProSense® offers the first new innovation in the treatment of women aged 70 and above with low-risk early-stage breast cancer in decades. We are proud to deliver a significant advancement and ...
Seeking Alpha

IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results

CAESAREA, Israel, Dec. 5, 2024 /PRNewswire/ -- IceCure Medical Ltd. (ICCM) (NASDAQ: ICCM) ('IceCure', 'IceCure Medical' or the 'Company'), developer of minimally-invasive cryoablation technology that ...
Kaleido Scope

UAB offers new minimally invasive treatment option for breast cancer patients

When cancer returned last year, it did so in a very different chapter of her life. This time, a rare stage IV sarcoma complicated her breast cancer. She now faced a difficult decision regarding ...
Seeking Alpha

IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery

After a median follow-up of 16 months, the complete ablation rate in Luminal A and B breast cancer tumors ≤ 25mm was 100% Study concluded that most non-surgical patients with early-stage breast cancer ...
Nasdaq

IceCure's ProSense System Used in Endometriosis Cryoablation Study That Demonstrated Efficacy Rate of 92.8% to Avoid Secondary Surgery

CAESAREA, Israel, April 20, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by ...
Morningstar

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in ...

CAESAREA, Israel, Oct. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for patients ...